Antimicrobial evaluation of some arylsulfanylpyrazinecarboxylic acid derivatives. 2007

Josef Jampilek, and Martin Dolezal, and Vladimir Buchta
Zentiva a.s., U kabelovny 130, 102 37 Prague 10, Czech Republic. josef.jampilek@zentiva.cz

The radical-ionic coupling of chloropyrazine-2-carboxylic acid derivatives with methoxybenzenethiols, carried out in the presence of a heterogeneous copper catalyst, provided the series of 6- or 5- or 3-(4-methoxyphenyl)sulfanyl-pyrazine-2-carboxylic acid derivatives as well as 6- or 5- or 3-(3-methoxyphenyl)sulfanylpyrazine-2-carboxylic acid derivatives. The prepared compounds were evaluated as potential antifungal agents and new antituberculotics. Their preliminary in vitro evaluation of antimycobacterial activity according to the international program with the Tuberculosis Antimicrobial Acquisition and Coordinating Facility (TAACF) is presented. Several compounds showed an interesting activity in the preliminary screening with a percentage growth inhibition of the virulent Mycobacterium tuberculosis H(37)Rv between 50 to 100% at the concentration 6.25 microg/mL. Structure-activity relationships among the chemical structure, the physical properties and the biological activities of the evaluated compounds are discussed in the article.

UI MeSH Term Description Entries
D009169 Mycobacterium tuberculosis A species of gram-positive, aerobic bacteria that produces TUBERCULOSIS in humans, other primates, CATTLE; DOGS; and some other animals which have contact with humans. Growth tends to be in serpentine, cordlike masses in which the bacilli show a parallel orientation. Mycobacterium tuberculosis H37Rv
D011719 Pyrazines A heterocyclic aromatic organic compound with the chemical formula C4H4N2. Pyrazine
D002264 Carboxylic Acids Organic compounds containing the carboxy group (-COOH). This group of compounds includes amino acids and fatty acids. Carboxylic acids can be saturated, unsaturated, or aromatic. Carboxylic Acid,Acid, Carboxylic,Acids, Carboxylic
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D000890 Anti-Infective Agents Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. Anti-Infective Agent,Anti-Microbial Agent,Antimicrobial Agent,Microbicide,Microbicides,Anti-Microbial Agents,Antiinfective Agents,Antimicrobial Agents,Agent, Anti-Infective,Agent, Anti-Microbial,Agent, Antimicrobial,Agents, Anti-Infective,Agents, Anti-Microbial,Agents, Antiinfective,Agents, Antimicrobial,Anti Infective Agent,Anti Infective Agents,Anti Microbial Agent,Anti Microbial Agents
D000935 Antifungal Agents Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. Anti-Fungal Agents,Antifungal Agent,Fungicides, Therapeutic,Antibiotics, Antifungal,Therapeutic Fungicides,Agent, Antifungal,Anti Fungal Agents,Antifungal Antibiotics
D000995 Antitubercular Agents Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. Anti-Tuberculosis Agent,Anti-Tuberculosis Agents,Anti-Tuberculosis Drug,Anti-Tuberculosis Drugs,Antitubercular Agent,Antitubercular Drug,Tuberculostatic Agent,Tuberculostatic Agents,Antitubercular Drugs,Agent, Anti-Tuberculosis,Agent, Antitubercular,Agent, Tuberculostatic,Anti Tuberculosis Agent,Anti Tuberculosis Agents,Anti Tuberculosis Drug,Anti Tuberculosis Drugs,Drug, Anti-Tuberculosis,Drug, Antitubercular
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships

Related Publications

Josef Jampilek, and Martin Dolezal, and Vladimir Buchta
January 2011, Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi,
Josef Jampilek, and Martin Dolezal, and Vladimir Buchta
April 1978, Journal of the American Oil Chemists' Society,
Josef Jampilek, and Martin Dolezal, and Vladimir Buchta
April 2012, Molecules (Basel, Switzerland),
Josef Jampilek, and Martin Dolezal, and Vladimir Buchta
November 1991, Archiv der Pharmazie,
Josef Jampilek, and Martin Dolezal, and Vladimir Buchta
August 1980, Die Pharmazie,
Josef Jampilek, and Martin Dolezal, and Vladimir Buchta
March 2011, Molecules (Basel, Switzerland),
Josef Jampilek, and Martin Dolezal, and Vladimir Buchta
July 2007, Archiv der Pharmazie,
Josef Jampilek, and Martin Dolezal, and Vladimir Buchta
December 2006, Acta pharmaceutica (Zagreb, Croatia),
Josef Jampilek, and Martin Dolezal, and Vladimir Buchta
July 2013, Bioorganic & medicinal chemistry letters,
Josef Jampilek, and Martin Dolezal, and Vladimir Buchta
January 2002, Arzneimittel-Forschung,
Copied contents to your clipboard!